SEC Company Response from Harpoon Therapeutics, Inc. (CIK 0001708493) — Mar 13, 2020
Harpoon Therapeutics, Inc. (CIK 0001708493)
Date: March 13, 2020 · CIK: 0001708493 · Accession: 0001193125-20-073069
AI Filing Summary & Sentiment
File numbers found in text: 333-237175
Letter
VIA EDGAR Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Harpoon Therapeutics, Inc. - Registration Statement on Form S-3 (File No. 333-237175)
Dear Sir or Madam:
On behalf of Harpoon Therapeutics, Inc. (the “Company”), we transmit for filing under the Securities Act of 1933, as amended, the Company’s Registration Statement on Form S-3 (File No. 333-237175) (the “Registration Statement”) for the registration of an aggregate of $250 million of securities of the Company, including shares of the Company’s common stock, preferred stock, debt securities and warrants for the purchase of common stock, preferred stock or debt securities.
Please note that, not later than 120 days after the end of the Company’s fiscal year and prior to requesting acceleration of effectiveness of the Registration Statement, the Company will file a definitive proxy statement for its 2020 Annual Meeting of Stockholders that will include the information required by Part III of Form 10-K.
Please direct any questions or comments regarding this filing to the undersigned at (415) 693-2174.
Sincerely,
Cooley LLP
Show Raw Text
CORRESP 1 filename1.htm CORRESP Jonie I. Kondracki T: +1 415 693 2174 jkondracki@cooley.com VIA EDGAR March 13, 2020 U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Harpoon Therapeutics, Inc. - Registration Statement on Form S-3 (File No. 333-237175) Dear Sir or Madam: On behalf of Harpoon Therapeutics, Inc. (the “Company”), we transmit for filing under the Securities Act of 1933, as amended, the Company’s Registration Statement on Form S-3 (File No. 333-237175) (the “Registration Statement”) for the registration of an aggregate of $250 million of securities of the Company, including shares of the Company’s common stock, preferred stock, debt securities and warrants for the purchase of common stock, preferred stock or debt securities. Please note that, not later than 120 days after the end of the Company’s fiscal year and prior to requesting acceleration of effectiveness of the Registration Statement, the Company will file a definitive proxy statement for its 2020 Annual Meeting of Stockholders that will include the information required by Part III of Form 10-K. Please direct any questions or comments regarding this filing to the undersigned at (415) 693-2174. Sincerely, Cooley LLP /s/ Jonie Ing Kondracki Jonie Ing Kondracki Cooley LLP 101 California Street 5th Floor San Francisco, CA 94111-5800 t: (415) 693-2000 f: (415) 693-2222 cooley.com